Evaluation of Cladribine treatment in refractory celiac disease type II

doi:10.3748/wjg.v17.i4.506

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4971)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

503

HTML

4213

Figures (1-3)

134

Tables (1-2)

121

Sum=4971

Jan 28, 2011 (publication date) through Apr 16, 2024

Times Cited of This Article

Times Cited (54)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jan 28, 2011; 17(4): 506-513
Published online Jan 28, 2011. doi: 10.3748/wjg.v17.i4.506

Full Size Figure Download Figure

Figure 3 Kaplan-Meier survival curves. A: Survival rate of responders and non-responders to cladribine treatment (Log Rank: P = 0.037). ¹3 patients died in the 1st and 5th year; ²1 patient died in the 2nd, 3rd and 4th year of follow-up; B: Survival rate of the pre-treatment (I) and the upfront 2-chlorodeoxyadenosine (II) group (Log Rank: P = 0.23). ¹4 patients died in the 1st year; ²1 patient died in the 1st, 3rd and 4th year; ³2 patients died in the 2nd year of follow-up.

Citation: Tack GJ, Verbeek WH, Al-Toma A, Kuik DJ, Schreurs MW, Visser O, Mulder CJ. Evaluation of Cladribine treatment in refractory celiac disease type II. World J Gastroenterol 2011; 17(4): 506-513
URL: https://www.wjgnet.com/1007-9327/full/v17/i4/506.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i4.506